Skip to content

Study · Animal study (in vivo) · 1986

3 results

Spinal action of dermorphin, an extremely potent opioid peptide from frog skin.

Stevens CW, Yaksh TL

Brain research1 Oct 1986Cited by 32 (Europe PMC)

PMID2877713 (opens in a new tab)DOI10.1016/0006-8993(86)91076-0 (opens in a new tab)PepBankPUB-02877713
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In animal tests, spinal dermorphin was more active than spinal morphine across hot plate, tail flick and writhing tests.

    In plain wordsIn animal tests, spinal dermorphin reduced pain responses more strongly than spinal morphine across hot plate, tail flick and writhing tests.

    Peptide
    Dermorphin
    Outcome
    IncreaseSpinal antinociceptive activity across hot plate, tail flick and writhing tests
    Study

    n: not reported in source

    Comparator
    spinal morphine
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated · spinalAs given in this study.

    Measurements

    Relative spinal activity
    3 to 5000 X
    versus spinal morphine across hot plate, tail flick and writhing tests

    Source sentences

    Summary
    Studies on the characteristics of spinally administered dermorphin, a novel heptapeptide isolated from the skin of South American Phyllomedusa frogs, indicated that this agent is 3-5000X more active spinal morphine on the hot plate, tail flick and writhing tests.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In animal tests, dermorphin displayed cross tolerance to spinal morphine.

    In plain wordsIn animal tests, dermorphin showed cross tolerance to spinal morphine.

    Peptide
    Dermorphin
    Outcome
    Not applicableCross tolerance to spinal morphine
    Study

    n: not reported in source

    Comparator
    spinal morphine
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · spinalAs given in this study.

    Source sentences

    Summary
    This agent displays naloxone reversibility and cross tolerance to spinal morphine, and possesses all of the characteristics of a mu opiate receptor agonist.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In animal tests, spinal dermorphin displayed naloxone reversibility.

    In plain wordsIn animal tests, naloxone reversed spinal dermorphin effects.

    Peptide
    Dermorphin
    Outcome
    Not applicableNaloxone reversibility
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · spinalAs given in this study.

    Source sentences

    Summary
    This agent displays naloxone reversibility and cross tolerance to spinal morphine, and possesses all of the characteristics of a mu opiate receptor agonist.
    1 context sentence
    Summary · context
    Studies on the characteristics of spinally administered dermorphin, a novel heptapeptide isolated from the skin of South American Phyllomedusa frogs, indicated that this agent is 3-5000X more active spinal morphine on the hot plate, tail flick and writhing tests.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.